open menu
3325 NW 70th Avenue
Miami, Florida,
33122
1.800.790.7520

Leadership

Terje van Schaik

Founder/President

Ms. Van Schaik is the founder and president of Greenspeed USA LLC. Having served as the Vice President of Aquaox LLC, a leading Electrochemical Activation Water technology company, Ms. Van Schaik gained extensive knowledge in Green environmental cleaning and disinfecting and was responsible for the company’s growth into residential and commercial markets.
“I founded Greenspeed because I wanted to expand on the work I started at Aquaox and provide people with safe, innovative and ecological products that work”  – Ms. Van Schaik.
Prior to her tenure at Aquaox, Ms. Van Schaik worked over 10 years for Estonia Air, first as a flight attendant and later in various levels of customer services. Her education includes a Bachelor of Science in Service Management from the Estonian Entrepreneurship University of Applied Sciences.

Michel van Schaik

Chief Executive Officer

Mr. van Schaik is the CEO of Greenspeed USA, LLC and principal of one of its technologies company, Aquaox, LLC. Mr. van Schaik is a pioneer in Electrochemical Activated (ECA) Water technology. Educated and obtaining a degree in business administration at HEAO, Arnhem, Netherlands in 1994, Mr. Van Schaik developed his skills and expertise in ECA technology in Europe before moving to the US 2006. He is considered the foremost expert and business leader in the development and use of ECA technology for green environmental cleaning and disinfection in field of health care.

Mr. van Schaik is the founding member and CEO of Aquaox LLC which is the country’s leading developer of patent-pending equipment for the production of Hypochlorouos Acid and Greenspeed USA, LLC which designs and develops proprietary equipment and systems to apply and use Hypochlorouos Acid solutions. These solutions have been identified by the Center of Disease Control to be one of the most powerful, effective, safe and sustainable disinfectants known to mankind.

Mr. van Schaiks solutions are registered with the Environmental Protection Agency (EPA), eliminate all known super bugs, bacteria, viruses and fungi within seconds and are significant components of his highly recognized, proprietary infection control system. Through the use of these products and developed protocols, he has dramatically reduced hospital acquired infections at numerous hospitals and set new standards in environmental services. He has developed proprietary electrolytic cells and computerized ECA Water generators for on–site production. These certified generators and solutions are currently in use at several locations throughout the United States, South America, Europe and Japan.

Mark Nagano

Vice President Operations

Mr. Nagano has more than 30 years of success in the Environmental Science industry, including senior management roles in sales, operations and support services. He is the current Vice President of Operations for Greenspeed, LLC located in Florida and is responsible for providing leadership, management, technology development and strategic planning.

Prior to joining Greenspeed, Mr. Nagano spent 25 years as Director of International Business & Technology Development for Tech Corporation, Ltd., a leading Japanese Environmental Science & Technology company located in Tokyo, Japan. Tech Corporation pioneered the development and commercialization of Electrolyzed Water, Food Waste Bio Digesters and Nanobubble Technology for which it received numerous patents. In addition, he held general management assignments in Southeast Asia, Oceania and Mexico. Mr. Nagano graduated with a bachelor’s degree in commerce and administration from Hiroshima University.


Advisory Board

Octavio Cieza, M.D.

A native of Peru, Dr. Cieza is the current Director of Infection Control and Epidemiology and Johnston UNC Health Care and received his medical degree from the National University of San Marcos in Lima. He completed his internship at The Christ Hospital in Cincinnati, OH, where he also completed an internal medicine residency.

Dr. Cieza finished a 2-year infectious disease joint fellowship program at the University of Chicago and the University of Illinois. He received HIV/AIDS clinical training at the University of Texas at Houston. Dr. Cieza has been involved in numerous clinical research trials and specializes in the diagnosis and treatment of infectious diseases. Dr. Cieza is fluent in English and Spanish.

Fred Ma, M.D.

Dr. Ma is a medical executive with over 26 years’ experience overseeing the strategic direction of pharmaceutical, biomedical, and medical device production. Currently he is the Chief Medical Officer at RMS Medical Products, Inc. His fields of expertise are in CNS, oncology, anti-inflammatory, anti-infectious, anti-fungal, wound healing, In vitro diagnostic, and other related disciplinary areas. He has advised top policy makers from the Food and Drug Administration (FDA), Center for Disease Control (CDC) as well as global regulatory agencies (e.g. EMA, WHO, Health Canada, TGA, PMDA, CFDA, etc.).

Dr. Ma successfully adopted an advanced surgical method along with the device for cervical vertebral decompression, fusions on disc herniation, was one of the first tier of neurosurgeons in China to introduce stereotactic neurosurgery to treat functional neuro-disorders, including epilepsy, Parkinson Disease, trigeminal neuralgia, and hemi-facial spasm and served as principal investigator for a WHO clinical research project at Tokyo University Hospital of Tokyo, Japan for malignant brain tumor clinical research (a large Phase III/IV study) – “Effects of Simultaneous Chemotherapy and Radiation on Malignant Gliaoma”.

Dr. Ma received his M.D. from Capital University of Medical Sciences, Beijing, his D.M.Sc. at University of Tokyo and his Ph.D. in Neuroscience from Rutgers University of New Jersey- Newark.

Dr. Ma is a medical executive with over 26 years’ experience overseeing the strategic direction of pharmaceutical, biomedical, and medical device production. Currently he is the Chief Medical Officer at RMS Medical Products, Inc. His fields of expertise are in CNS, oncology, anti-inflammatory, anti-infectious, anti-fungal, wound healing, In vitro diagnostic, and other related disciplinary areas.

He has advised top policy makers from the Food and Drug Administration (FDA), Center for Disease Control (CDC) as well as global regulatory agencies (e.g. EMA, WHO, Health Canada, TGA, PMDA, CFDA, etc.). Dr. Ma successfully adopted an advanced surgical method along with the device for cervical vertebral decompression, fusions on disc herniation, was one of the first tier of neurosurgeons in China to introduce stereotactic neurosurgery to treat functional neuro-disorders, including epilepsy, Parkinson Disease, trigeminal neuralgia, and hemi-facial spasm and served as principal investigator for a WHO clinical research project at Tokyo University Hospital of Tokyo, Japan for malignant brain tumor clinical research (a large Phase III/IV study) – “Effects of Simultaneous Chemotherapy and Radiation on Malignant Gliaoma”.

Dr. Ma received his M.D. from Capital University of Medical Sciences, Beijing, his D.M.Sc. at University of Tokyo and his Ph.D. in Neuroscience from Rutgers University of New Jersey- Newark.